TY - JOUR
T1 - Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
AU - Murphy, Robert L.
AU - Sommadossi, Jean Pierre
AU - Lamson, Michael
AU - Hall, David B.
AU - Myers, Maureen
AU - Dusek, Alex
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1999
Y1 - 1999
N2 - Nevirapine and indinavir have the potential of affecting the pharmacokinetics of each other. In a prospective trial, 24 human immunodeficiency virus (HIV)-infected subjects on stable nucleoside or no therapy were treated with 800 mg of indinavir every 8 h. After 7 days, 200 mg of nevirapine a day was added for 14 days and then increased to 200 mg twice a day. At day 7 (before nevirapine), there was a sevenfold difference among the subjects in indinavir area under the curve (AUC), and there was a significant correlation between indinavir AUC (r2 = 0.378, P = .019), minimum plasma concentration (C(min); r2 = 0.359, P = .023), maximum plasma concentration (C(max); r2 = 0.340, P = .028), and plasma HIV RNA decline. Nevirapine significantly reduced median indinavir C(min) (47.5%) and AUC (27.4%) and, to a lesser extent, C(max) (11%). Plasma HIV RNA values were < 1/2 0 copies/mL in 10 of 17 (58.8%) subjects at 58 weeks or last visit. These data suggest that indinavir dosing should be dependent on drug exposure and not on cotherapy with nevirapine.
AB - Nevirapine and indinavir have the potential of affecting the pharmacokinetics of each other. In a prospective trial, 24 human immunodeficiency virus (HIV)-infected subjects on stable nucleoside or no therapy were treated with 800 mg of indinavir every 8 h. After 7 days, 200 mg of nevirapine a day was added for 14 days and then increased to 200 mg twice a day. At day 7 (before nevirapine), there was a sevenfold difference among the subjects in indinavir area under the curve (AUC), and there was a significant correlation between indinavir AUC (r2 = 0.378, P = .019), minimum plasma concentration (C(min); r2 = 0.359, P = .023), maximum plasma concentration (C(max); r2 = 0.340, P = .028), and plasma HIV RNA decline. Nevirapine significantly reduced median indinavir C(min) (47.5%) and AUC (27.4%) and, to a lesser extent, C(max) (11%). Plasma HIV RNA values were < 1/2 0 copies/mL in 10 of 17 (58.8%) subjects at 58 weeks or last visit. These data suggest that indinavir dosing should be dependent on drug exposure and not on cotherapy with nevirapine.
UR - http://www.scopus.com/inward/record.url?scp=0033046403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033046403&partnerID=8YFLogxK
U2 - 10.1086/314703
DO - 10.1086/314703
M3 - Article
C2 - 10191212
AN - SCOPUS:0033046403
VL - 179
SP - 1116
EP - 1123
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 5
ER -